Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Effects of intensive glucose lowering in type 2 diabetes.

H. Gerstein, Michael E. Miller, R. Byington, et al.. (2008). The New England journal of medicine. Cited 4,919 times. https://doi.org/10.1056/NEJMoa0802743

Effects of combination lipid therapy in type 2 diabetes mellitus.

H. Ginsberg, M. Elam, L. Lovato, et al.. (2010). The New England journal of medicine. Cited 2,663 times. https://doi.org/10.1056/NEJMoa1001282

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.

J. Buse, J. Bigger, R. Byington, et al.. (2007). The American journal of cardiology. Cited 627 times. https://doi.org/10.1016/J.AMJCARD.2007.03.003

Effects of intensive blood-pressure control in type 2 diabetes mellitus.

William C. Cushman, Gregory W Evans, R. Byington, et al.. (2010). The New England journal of medicine. Cited 620 times. https://doi.org/10.1056/NEJMoa1001286

Variation in the Glucose Transporter gene SLC2A2 is associated with glycaemic response to metformin

K. Zhou, S. Yee, E. Seiser, et al.. (2016). Nature genetics. Cited 193 times. https://doi.org/10.1038/ng.3632

Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial

Hetal S. Shah, He Gao, M. Morieri, et al.. (2016). Diabetes Care. Cited 49 times. https://doi.org/10.2337/dc16-0285

A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies

M. Irvin, D. Rotroff, S. Aslibekyan, et al.. (2016). Pharmacogenetics and Genomics. Cited 13 times. https://doi.org/10.1097/FPC.0000000000000219

Common and rare genetic markers of lipid variation in subjects with type 2 diabetes from the ACCORD clinical trial

Skylar W. Marvel, D. Rotroff, M. Wagner, et al.. (2017). PeerJ. Cited 13 times. https://doi.org/10.7717/peerj.3187

Variants in ANGPTL4 and the Risk of Coronary Artery Disease.

M. Morieri, Hetal S. Shah, A. Doria. (2016). The New England journal of medicine. Cited 6 times. https://doi.org/10.1056/NEJMc1607380

Characteristics associated with informed consent for genetic studies in the ACCORD trial.

D. Simons-Morton, Jeffrey C Chan, A. Kimel, et al.. (2014). Contemporary clinical trials. Cited 5 times. https://doi.org/10.1016/j.cct.2013.12.002

Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response

H. Graham, D. Rotroff, Skylar W. Marvel, et al.. (2016). Frontiers in Genetics. Cited 3 times. https://doi.org/10.3389/fgene.2016.00138